240 related articles for article (PubMed ID: 24613115)
1. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
Hanif R; Mansoor S
J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
[TBL] [Abstract][Full Text] [Related]
2. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
[TBL] [Abstract][Full Text] [Related]
3. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
4. Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1.
Sugiki T; Yamamoto M; Aruga A; Takasaki K; Nakano M
J Surg Oncol; 2004 Nov; 88(2):104-7. PubMed ID: 15499598
[TBL] [Abstract][Full Text] [Related]
5. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Leong AS; Sormunen RT; Tsui WM; Liew CT
Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920
[TBL] [Abstract][Full Text] [Related]
6. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
Lau SK; Prakash S; Geller SA; Alsabeh R
Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract][Full Text] [Related]
8. Immunoreactivity of hepatocyte paraffin 1 monoclonal antibody in cutaneous metastatic tumors.
Kanitakis J; Chouvet B; Claudy A; Scoazec JY
Am J Clin Pathol; 2004 Jul; 122(1):85-9. PubMed ID: 15272534
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.
Nguyen T; Phillips D; Jain D; Torbenson M; Wu TT; Yeh MM; Kakar S
Arch Pathol Lab Med; 2015 Aug; 139(8):1028-34. PubMed ID: 26230595
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
11. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.
Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ
Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples.
Lugli A; Tornillo L; Mirlacher M; Bundi M; Sauter G; Terracciano LM
Am J Clin Pathol; 2004 Nov; 122(5):721-7. PubMed ID: 15491968
[TBL] [Abstract][Full Text] [Related]
13. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.
Fan Z; van de Rijn M; Montgomery K; Rouse RV
Mod Pathol; 2003 Feb; 16(2):137-44. PubMed ID: 12591966
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous metastasis of hepatocellular carcinoma diagnosed by fine needle aspiration cytology and Hep Par 1 immunopositivity.
Isa NM; Bong JJ; Ghani FA; Rose IM; Husain S; Azrif M
Diagn Cytopathol; 2012 Nov; 40(11):1010-4. PubMed ID: 21563319
[TBL] [Abstract][Full Text] [Related]
15. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma.
Niemann TH; Hughes JH; De Young BR
Cancer; 1999 Oct; 87(5):295-8. PubMed ID: 10536355
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours.
Majeed S; Mushtaq S; Azam M; Akhtar N; Hussain M; Loya A
J Pak Med Assoc; 2018 Jul; 68(7):1029-1031. PubMed ID: 30317296
[TBL] [Abstract][Full Text] [Related]
17. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
Geramizadeh B; Boub R; Rahsaz M
Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
[TBL] [Abstract][Full Text] [Related]
18. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
Chu PG; Ishizawa S; Wu E; Weiss LM
Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract.
Maitra A; Murakata LA; Albores-Saavedra J
Am J Clin Pathol; 2001 May; 115(5):689-94. PubMed ID: 11345832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
